In relation to the different methylation classes reported to independently stratify for risk of recurrence among meningioma [12], CDKN2A/B homozygous deletion was observed only in the methylation classes “intermediate” (n = 6; 23%) or “malignant” (n = 20; 77%). Here, CDKN2A is linked to meningioma.